Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Cytek Biosciences, Inc.NASDAQ: CTKB

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -42.7%

Net margin was -42.7% in Q1 FY2026, down 15.2 pp from a year earlier. On a trailing-twelve-month basis it was -36.2%, down 30.5 pp year over year. Over 3 fiscal years it narrowed by 34.6 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 2 analysts of -17.5% for the fiscal year ending Dec 2026, up from -33.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-42.7%+28.2 pp QoQ
Last fiscal yearDec 2025
-33.0%-30.0 pp YoY
LTMMar 2026
-36.2%-30.5 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-15.2 pp-13.5 pp+1.8 pp
1 year-30.0 pp+15.5 pp+45.6 pp
3 years-34.6 pp+27.3 pp+61.9 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-33.0%
Year-over-year change
-30.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's LTM Mar 2026 net margin of -36.2% is the 5th highest of the 6 companies compared; the peer median is -2.0%.
  • Its year-over-year change of -30.5 pp is the lowest of 6, against a peer median of -3.9 pp.
  • Over three fiscal years its change of -34.6 pp compares with a peer median of +25.4 pp.
CTKB Competitors Peer median
Net Margin for CTKB and competitors
Company Period LTM level YoY 3-year change
AAgilent Technologies, Inc.LTM Jul 202619.5% +1.6 pp+0.4 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 20268.6% -3.9 pp+158.9 pp
BRKRBruker CorporationLTM Jun 2026-2.0% -4.3 pp-12.0 pp
TXG10x Genomics, Inc.LTM Sep 2026-10.8% +1.0 pp+25.4 pp
CTKBCytek Biosciences, Inc.LTM Mar 2026-36.2% -30.5 pp-34.6 pp
LABStandard BioTools Inc.LTM Mar 2026-109.1% -10.3 pp+106.3 pp
Peer median (excluding CTKB) -2.0%-3.9 pp+25.4 pp

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue127.95M164.04M193.02M200.45M201.49M
Cost of Revenue48.81M63.06M83.59M89.35M97.03M
Gross Profit79.14M100.97M109.43M111.11M104.46M
Gross Margin61.9%61.6%56.7%55.4%51.8%
Research & Development24.44M34.86M44.15M39.4M36.47M
Selling, General & Admin45.55M67.92M93.12M92.23M108.38M
Operating Expenses69.99M102.78M137.27M131.63M144.84M
Depreciation & Amortization1.24M5.66M9.23M10.49M11.98M
EBITDA8.92M9.49M(4.41M)4.79M(17.39M)
EBITDA Margin7.0%5.8%-2.3%2.4%-8.6%
Operating Income9.16M(1.8M)(27.85M)(20.52M)(40.38M)
Operating Margin7.2%-1.1%-14.4%-10.2%-20.0%
Interest Income49K4.62M6.41M10.36M2.22M
Interest Expense1.74M2.57M2.07M0474K
Other Income / Expenses(3.22M)3.06M12.14M14.82M10.54M
Income Before Tax5.94M1.26M(15.71M)(5.7M)(29.84M)
Pre-Tax Margin4.6%0.8%-8.1%-2.8%-14.8%
Income Tax Expense2.91M(1.22M)(3.56M)320K36.7M
Net Income3M2.58M(12.15M)(6.02M)(66.54M)
Net Margin2.3%1.6%-6.3%-3.0%-33.0%
EPS (Basic)0.030.02(0.09)(0.05)(0.52)
EPS (Diluted)0.030.02(0.09)(0.05)(0.52)
Weighted Avg Shares133.75M134.51M135.28M130.61M127.75M
Weighted Avg Shares (Diluted)133.75M138.56M135.28M130.61M127.75M

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.